CLINICAL_TRIALS
trial_result
· 2026-02-05
Clinical Trial Update: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 [Phase 3]
Summary
A Phase 3 study of dolutegravir in HIV-1 participants completing IMPAACT trials P1093 and P2019 has completed, with results posted on 2026-02-05.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2026-02-05